Menu


Antimicrobial resistance (AMR) is now a major global public health threat. Despite the recognized need for new antimicrobials for clinical use, the reality that only two new classes of antibiotics have been brought to market in the last 30 years and many drug developers have left the field. ND4BB is part of the 
“Action plan against the rising threats from Antimicrobial Resistance” adopted by the European Commission in answer to the Council Conclusions and European Parliament resolution to “establish an EU-wide plan to combat AMR.

New Drugs for Bad Bugs aims to join forces between public and private partners in order  to bring new antimicrobials closer to patients, to share information and to boost research on improving the uptake (and decreasing the efflux) of antibiotics into Gram-negative bacteria which is one of the greatest challenges facing drug discovery for Gram-negative pathogens.

New Drugs 4 Bad Bugs
 
 
Topic1 Topic2 Topic3 topic4 Topic5
  arrow      
  Topic2down